Dec 19, 2022, 12:12 PM by

Creative Biolabs identifies a suite of exosome services to advance basic research based on microRNAs-associated extracellular vesicles as novel diagnostic tools for melanoma.

Dec 19, 2022, 12:10 PM by

OncoDxRx scientists has described the combination of NGS and PGA as ‘world beating’ offering that will complete the test menu and benefit entire population of cancer patients.

Dec 16, 2022, 09:51 AM by

Integrated Synthesis-to-Clinic® Program Will Support HTD1801’s Clinical Development and Regulatory Submission Package

Dec 16, 2022, 01:00 AM by User Not Found

Bio-IT World | The rush to digitalization has been underway for some time, but there is one industry that remains stuck in the past: the life sciences. While there have been numerous advancements in the way drugs are developed, lab work continues to be dominated by out-of-date processes. Improving them isn’t going to move the dial. While they may help, they are not capable of producing the level of innovation that’s needed to take us to the next phase.

Dec 15, 2022, 09:59 AM by

New evidence demonstrates that NoriZite creates a physical barrier to prevent viral infection

Dec 15, 2022, 09:59 AM by

physIQ today announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable biosensors and deep neural network technology. This innovative biomarker, eVO2Max, can be generated using 24 hours of continuous vital signs and activity data captured during routine daily activities. This enables remote assessment at higher frequency and convenience than by in-clinic tests of cardiopulmonary functional capacity, such as the gold standard, cardiopulmonary exercise test (CPET), and the less accurate surrogate six-minute walk test (6MWT).

Dec 15, 2022, 01:01 AM by User Not Found

Bio-IT World | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

Dec 15, 2022, 01:00 AM by User Not Found

Bio-IT World | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

Dec 14, 2022, 15:18 PM by

PubHive Navigator’s Fetch version 2.0 features new content curator and consumer roles, expanded data input and output options, integration capabilities, plus a simplified consumer user interface

Dec 14, 2022, 10:08 AM by

Form Bio, the breakthrough computational life sciences platform, today announced the integration of the NVIDIA Clara Parabricks suite of genomic analysis tools with Form Bio’s genomic analysis workflows. The integrated solution, provided by Form Bio, enables scientists, bioinformaticians and other life science professionals to execute genomic workflows with acceleration fueled by GPU parallelization and deep learning AI tools.

Dec 14, 2022, 10:08 AM by

Company focused on creating shot-free future of vaccines and expanding vaccine access; first human trial of Vaxess patch-based influenza vaccine showed strong safety and immunogenicity profiles

Dec 14, 2022, 10:08 AM by

InSysBio launches the Oncology version of Immune Response Template (IRT). IRT in Oncology represents a QSP platform of immune system in cancer, simultaneously being a tool for development of QSP and mechanistic models related to tumor-specific immune response.

Dec 14, 2022, 10:05 AM by

New innovation delivers optimal product conditions in fewer runs, reducing raw materials costs, and shaving weeks off of Process Development campaigns

Dec 14, 2022, 09:48 AM by

Qlucore will be participating in a major EU project that is working to improve preventative treatment for patients at risk of cardiovascular diseases, such as heart attacks and strokes.

Dec 14, 2022, 09:45 AM by

On the occasion of Thanksgiving and Christmas, Alfa Chemistry would like to express its sincere gratitude to its global customers. In addition to discounts and exquisite gifts offered to ordering customers, the company also continuously improves its product lines. Fairly recently, Alfa Chemistry announced the upgrade of its featured products, i.e., protection reagents, environmental goods standards, as well as porphyrins and phthalocyanines, supporting better user experience and wider choices for customers across the world.

Dec 14, 2022, 09:43 AM by

The past decade has seen exponential growth of the cosmeceutical market in the personal care industry. There is increasing use of alpha hydroxy acids for skin rejuvenation as well as the use of vitamin C in topical formulations as an antioxidant. In response to such a trend, CD Formulation recently launched one-stop OEM/ODM and analytical testing solutions for cosmetic formulations.

Dec 14, 2022, 09:40 AM by

Start-up trials achieved in eight to 12 weeks, a fraction of typical timeframe

Dec 14, 2022, 09:38 AM by

Large teaching hospital in the Netherlands relies on precision dosing platform for point-of-care decision support and immunology research

Dec 14, 2022, 09:37 AM by

DrFirst’s MedHx PRM Provides Quick Access to Prescription Fill Information So Healthcare Providers Can Intervene Early to Prevent Readmissions and Optimize Outcomes

Dec 14, 2022, 01:00 AM by User Not Found

Bio-IT World | Researchers from Duke, Penn State, and the University of Tennessee collaboratively built a mathematical model of Alzheimer’s disease that used real, de-identified patient data to simulate health outcomes from a pair of anti-amyloid-beta drugs. Notably, the virtual (aka in silico) clinical trials employed a computational approach that provides “individualized prescriptions” based on optimal timing and dosing of treatment while minimizing possible side effects.